文献速递瓣膜外科

孤立性主动脉瓣置换同期房颤消融的安全性

Safety of Atrial Fibrillation Ablation With Isolated Surgical Aortic Valve Replacement.
PubMed 文献 · Ann Thorac Surg · 2020-08-11

基于STS数据库2014-2017年87,426例孤立性主动脉瓣置换患者,术前房颤占17.8%,其中33.1%行消融。倾向评分匹配后,消融组与未消融组30天死亡率(2.8% vs 3.0%,P=.65)和卒中率(1.6% vs 1.7%,P=.82)无差异,但消融组术后起搏器植入率更高(6.8% vs 5.0%,P<.001)。

要点

  • 术前房颤患者中仅33.1%同期行消融,远低于STS指南I类推荐。
  • 消融未增加30天死亡率和卒中风险,但起搏器植入率显著升高。
  • 孤立性主动脉瓣置换患者中房颤常被忽略,需提高消融实施率。

核心结论

  • 尽管房颤消融是STS指南I类推荐,但在外科主动脉瓣置换患者中实施率仍低于推荐。
  • 房颤消融不增加30天手术死亡率或围术期并发症,但新起搏器需求更高。

研究设计与样本

  • 回顾性分析STS数据库(版本2.81,2014-2017)87,426例孤立性主动脉瓣置换患者。
  • 分为无术前房颤组、术前房颤行消融组和术前房颤未行消融组,后两组按1:2倾向评分匹配。

主要发现

  • 术前房颤患病率为17.8%(15,596/87,426)。
  • 房颤患者中33.1%(5,167/15,596)行消融,57.7%(2,983)行左心耳闭合。
  • 匹配后(消融组n=3692,未消融组n=5724),30天死亡率2.8% vs 3.0%(P=.65),卒中率1.6% vs 1.7%(P=.82)。
  • 消融组术后起搏器植入率6.8%,未消融组5.0%(P<.001)。

关键数值与推荐

  • STS指南将房颤同期消融列为I类推荐。
  • 匹配后消融组与未消融组30天死亡率无显著差异(2.8% vs 3.0%,P=.65)。
  • 匹配后消融组起搏器植入率显著高于未消融组(6.8% vs 5.0%,P<.001)。

临床怎么用

  • 在孤立性主动脉瓣置换患者中应积极评估并实施同期房颤消融,因其不增加30天死亡风险。
  • 术前需告知患者消融后起搏器植入风险可能升高。

局限性

  • 研究为回顾性数据库分析,可能存在未测量混杂。
  • 仅评估30天结局,缺乏长期疗效数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical ablation of atrial fibrillation (AF) concomitant with cardiac surgery is a Society of Thoracic Surgeons (STS) class I recommendation, although the AF is frequently ignored. Analysis of the STS Database 30-day outcomes of isolated surgical aortic valve replacement (AVR) with and without AF ablation is presented. METHODS: Data on 87,426 surgical aortic valve replacement patients were extracted from the STS database (version 2.81, 2014-2017) and patients were divided into 3 groups: (1) No preoperative AF, (2) Preoperative AF with concomitant ablation, and (3) Preoperative AF without ablation. The latter 2 groups were propensity score-matched in 1-(up)-to-2 ratio to alleviate covariate imbalances and reduce bias. Thirty-day outcomes were evaluated and compared. RESULTS: Preoperative AF was present in 17.8% (15,596 of 87,426 patients). Ablation was performed in 33.1% (5,167 of 15,596), and 57.7% (2,983) had left atrial appendage closure. Propensity score matching (AF ablated n = 3692; AF non-ablated n = 5724), revealed that there was no difference between the AF ablated and AF non-ablated groups in mortality (2.8% vs 3.0%, respectively; P = .65) or for stroke (1.6% vs 1.7%, respectively; P = .82), but postoperative pacemaker implantation was higher in the AF ablated patients (6.8% AF ablated vs 5.0% AF non-ablated, P < .001). CONCLUSIONS: Despite being a class I recommendation, AF ablation concomitantly with other cardiac surgical procedures remains lower than current guideline recommendation in surgical aortic valve replacement patients. Ablation for AF does not increase the 30-day operative mortality or perioperative morbidity compared with non-ablated patients, although new pacemaker requirements were higher in the AF ablated group.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Churyla A, Andrei AC, Kruse J, et al. Safety of Atrial Fibrillation Ablation With Isolated Surgical Aortic Valve Replacement. Ann Thorac Surg. 2020. PMID: 32791060. doi:10.1016/j.athoracsur.2020.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。